Trial intelligence / Profile preview

LW402 in Moderate-to-Severe Atopic Dermatitis

CTR20230544Phase 2Completed

Sponsor
Shanghai Changsen Pharmaceutical
Start
Mar 2023
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of lw402 in atopic dermatitis (AD), sponsored by Shanghai Changsen Pharmaceutical. Started Mar 2023; status: completed.

02

Drugs

lw402
03

Conditions

atopic dermatitis (AD)

Beyond the preview

Go deeper on CTR20230544.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20230544.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call